Aberrant levels of inflammatory mediators that changed with ERG expressions have also been discovered, and the imbalance of inflammatory mediators might impact the progression of ERG-positive prostate cancer with some loss of immune capability involving HLA-DMB molecule and CD3+ cells [79]. This evidence concerns the gene ERG and prostate cancer.